

## The ARRIVE guidelines 2.0: author checklist

## The ARRIVE Essential 10

These items are the basic minimum to include in a manuscript. Without this information, readers and reviewers cannot assess the reliability of the findings.

ltem		Recommendation	Section/line number, or reason for not reporting
Study design	1	For each experiment, provide brief details of study design including:	133-135
		a. The groups being compared, including control groups. If no control group has been used, the rationale should be stated.	132
		b. The experimental unit (e.g. a single animal, litter, or cage of animals).	132
Sample size	2	<ul> <li>Specify the exact number of experimental units allocated to each group, and the total number in each experiment. Also indicate the total number of animals used.</li> </ul>	132(5 for each group a total of 20 mice)
		b. Explain how the sample size was decided. Provide details of any <i>a priori</i> sample size calculation, if done.	not reporting, based on the number of animals used in general experiments.
Inclusion and exclusion criteria	3	a. Describe any criteria used for including and excluding animals (or experimental units) during the experiment, and data points during the analysis. Specify if these criteria were established <i>a priori</i> . If no criteria were set, state this explicitly.	Tumor volume was significantly different from that of other mice in the group.
		b. For each experimental group, report any animals, experimental units or data points not included in the analysis and explain why. If there were no exclusions, state so.	no exclusions
		c. For each analysis, report the exact value of <i>n</i> in each experimental group.	132
Randomisation	4	a. State whether randomisation was used to allocate experimental units to control and treatment groups. If done, provide the method used to generate the randomisation sequence.	yes, each mouse was numbered and randomly divided into four groups. All animals were fed in SP
		<ul> <li>Describe the strategy used to minimise potential confounders such as the order of treatments and measurements, or animal/cage location. If confounders were not controlled, state this explicitly.</li> </ul>	laboratory under the same conditions, given the sam diet, and tumor volume wa measured regularly.
Blinding	5	Describe who was aware of the group allocation at the different stages of the experiment (during the allocation, the conduct of the experiment, the outcome assessment, and the data analysis).	In animal experiments, under t guidance of teachers in animal laboratory, the first author Hui- ying Huang completed tumor of injection, mouse numbering, tumor body measurement and data recording.
Outcome measures	6	<ul> <li>Clearly define all outcome measures assessed (e.g. cell death, molecular markers, or behavioural changes).</li> </ul>	137-138
		b. For hypothesis-testing studies, specify the primary outcome measure, i.e. the outcome measure that was used to determine the sample size.	136-138
Statistical methods	7	a. Provide details of the statistical methods used for each analysis, including software used.	140-142
		b. Describe any methods used to assess whether the data met the assumptions of the statistical approach, and what was done if the assumptions were not met.	140-142
Experimental animals	8	a. Providespecies-appropriate details of the animals used, including species, strain and substrain, sex, age or developmental stage, and, if relevant, weight.	131
		b. Provide further relevant information on the provenance of animals, health/immune status, genetic modification status, genotype, and any previous procedures.	131
Experimental procedures	9	For each experimental group, including controls, describe the procedures in enough detail to allow others to replicate them, including:	In the section: Tumorigenicity assay in nude mice.
		a. What was done, how it was done and what was used.	133-135
		b. When and howoften.	133-135
		<ul><li>c. Where (including detail of any acclimatisation periods).</li><li>d. Why (provide rationale for procedures).</li></ul>	133-135
Results	10	For each experiment conducted, including independent replications, report:	The results of the data analysi are presented in Figure 6,
		a. Summary/descriptive statistics for each experimental group, with a measure of variability where applicable (e.g. mean and SD, or median and range).	indicating significant difference in tumor volume between groups. The results of the data
		b. If applicable, the effect size with a confidence interval.	analysis are presented in Figure 6, with intra-group differences represented by bar values.

## The Recommended Set

These items complement the Essential 10 and add important context to the study. Reporting the items in both sets represents best practice.

ltem		Recommendation	Section/line number, or reason for not reporting
Abstract	11	Provide an accurate summary of the research objectives, animal species, strain and sex, key methods, principal findings, and study conclusions.	Animal experiments are mainly used to verify the results of cell experiments and are not described in detail.
Background	12	<ul> <li>Include sufficient scientific background to understand the rationale and context for the study, and explain the experimental approach.</li> </ul>	26-28
		b. Explain how the animal species and model used address the scientific objectives and, where appropriate, the relevance to human biology.	32-33
Objectives	13	Clearly describe the research question, research objectives and, where appropriate, specific hypotheses being tested.	59-62
Ethical statement	14	Provide the name of the ethical review committee or equivalent that has approved the use of animals in this study, and any relevant licence or protocol numbers (if applicable). If ethical approval was not sought or granted, provide a justification.	256-260
Housing and husbandry	15	Provide details of housing and husbandry conditions, including any environmental enrichment.	The experimental animals were uniformly raised in the SPF animal center with constant temperature, fed by the center management staff and replaced with bedding materials. The animal center keeps the environment clean and tidy, and all laboratory operations are carried out in the operation room with as little operation time as possible.
Animal care and monitoring	16	<ul> <li>a. Describe any interventions or steps taken in the experimental protocols to reduce pain, suffering and distress.</li> <li>b. Report any expected or unexpected adverse events.</li> <li>c. Describe the humane endpoints established for the study, the signs that were monitored and the frequency of monitoring. If the study did not have humane endpoints, state this.</li> </ul>	Tumor volume was monitored weekly and mice were sacrificed before tumor length exceeded 1.5cm. In order to reduce the pain of mice, inhalation anesthesia equipment was used for small animals. After anesthesia, cervical dislocation was performed and tumor tissue was taken.
Interpretation/ scientific implications	17	<ul> <li>a. Interpret the results, taking into account the study objectives and hypotheses, current theory and other relevant studies in the literature.</li> <li>b. Comment on the study limitations including potential sources of bias, limitations of the animal model, and imprecision associated with the results.</li> </ul>	187-189
Generalisability/ translation	18	Comment on whether, and how, the findings of this study are likely to generalise to other species or experimental conditions, including any relevance to human biology (where appropriate).	This study can be extended to the combination of targeted drugs for other tumors
Protocol registration	19	Provide a statement indicating whether a protocol (including the research question, key design features, and analysis plan) was prepared before the study, and if and where this protocol was registered.	Not available
Data access	20	Provide a statement describing if and where study data are available.	All the source data supporting the findings of this study are available from the corresponding author upon reasonable request.
Declaration of interests	21	<ul><li>a. Declare any potential conflicts of interest, including financial and non-financial. If none exist, this should be stated.</li><li>b. List all funding sources (including grant identifier) and the role of the funder(s) in the design, analysis and reporting of the study.</li></ul>	254-255

ticle information: https://dx.doi.org/10.21037/tcr-21-2325 the checklist was provided upon initial submission, the section/line number reported may be changed due to copyediting and may not be referable in the published version.



www.ARRIVEguidelines.org